Retatrutide, by Soma Corp., is gaining considerable attention as a novel treatment for metabolic management . This dual-action drug combines the mechanism of a GLP-1 receptor activator and a GIP receptor agonist , designed to effectively promote metabolic improvements but also address underlying metabolic issues . Initial patient trials have demons